PNH and aHUS Market From US$ 5.9 Billion to US$ 10.5 Billion by 2034
Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) are rare, life-threatening disorders associated with dysregulation of the complement system. Increasing awareness of rare diseases, growing access to advanced diagnostic tools, and the development of targeted biologic therapies are significantly transforming the treatment landscape. Pharmaceutical companies...
0 التعليقات
0 نشر
174 ظهور